Diagnosis and management of hemochromatosis

Hepatology

Volumn 33, Issue 5, 2001, Pages 1321-1328

  Tavill, A S ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; GENETIC DISORDER; GENOTYPE; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; PATHOGENESIS; PHENOTYPE; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0035038147     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.24783     Document Type: Article

References (50)

1. Position and policy statement. American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers
2. Infectious diseases society of america quality standards for infectious diseases: Purpose of quality standards for infectious diseases
3. Global prevalence of putative haemochromatosis mutations
4. Celtic origin of the C282Y mutation of hemochromatosis
5. A population based study of the clinical expression of the hemochromatosis gene
6. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis
7. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients
8. Inherited HFE-unrelated hemochromatosis in Italian families
9. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene
10. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis
11. Expression of HLA-linked hemochromatosis in subjects homozygous for the C282Y mutation
12. Screening blood donors for hereditary hemochromatosis. Decision analysis model based on a 30 year database
13. Genotypic/phenotypic correlations in genetic hemochromatosis: Evolution of diagnostic criteria
14. Long-term survival in patients with hereditary hemochromatosis
15. Value of hepatic iron measurement in early hemochromatosis and determination of the critical iron level associated with fibrosis
16. Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index
17. Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic hemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis
18. Utility of hepatic iron index in American patients with hereditary hemochromatosis: A multicenter study
19. HFE genotype in patients with hemochromatosis and other liver diseases
20. Screening for hemochromatosis: A cost-effectiveness study based on 12,258 patients
21. Cost-effectiveness of screening for hereditary hemochromatosis
22. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older
23. Analysis of the cost of population screening for hemochromatosis using biochemical and genetic markers
24. Screening blood donors for hereditary hemochromatosis: Decision analysis model comparing genotyping to phenotyping
25. Screening for hemochromatosis: Phenotyping or genotyping or both?
26. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors
27. Diagnostic efficacy of screening tests for hereditary hemochromatosis
28. Diagnosis of hemochromatosis in young subjects: Predictive accuracy of biochemical screening tests
29. Distribution of transferrin saturation in an Australian population: Relevance to the early diagnosis of hemochromatosis
30. Population screening for hemochromatosis: A comparison of unbound iron binding capacity transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors
31. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis
32. Molecular medicine and hemochromatosis: At the crossroads
33. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: A study of 192 cases
34. Hepatic pathology in relatives of patients with hemochromatosis
35. Liver biopsy diagnosis of homozygous hemochromatosis: A diagnostic algorithm
36. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: Diagnostic implications
37. Primary liver cancer in genetic hemochromatosis: A clinical pathological and pathogenic study of 54 cases
38. Outcome of liver transplantation in patients with hemochromatosis
39. Primary liver cancer and survival in hereditary hemochromatosis patients undergoing orthotopic liver transplantation
40. The β-thalassemias
41. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
42. A risk-benefit assessment of iron chelation therapy
43. Hepatic iron stores and plasma ferritin concentration in patients with sickle ceil anemia and thalassemia major
44. Limitations of magnetic resonance imaging in measurement of hepatic iron
45. Phlebotomy to reduce iron overload in patients cured of thalassemia by some marrow transplantation
46. Hepatic iron concentration and total body iron stores in thalassemia major
47. Clinical implications of the hemochromatosis gene
48. EASL International Consensus Conference on Haemochromatosis